Search
forLearn
5 / 801 resultslearn oligopeptide-71
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn microbiota modulator
learn HT-B
Research
5 / 230 results
research miR-195-5p Regulates Hair Follicle Inductivity of Dermal Papilla Cells by Suppressing Wnt/β-Catenin Activation
miR-195-5p reduces hair growth ability in cells by blocking a specific growth signal.
research LncRNA-miRNA-mRNA regulatory networks in skin aging and therapeutic potentials
ceRNA networks offer potential treatments for skin aging and wound healing.
research Platelet-Rich Plasma Therapy for Telogen Effluvium: A Comprehensive Evaluation of Efficacy and Safety
Combining PRP with Tressfix Serum is more effective for hair regrowth in telogen effluvium than using either alone.
research Current insight into the functions of microRNAs in common human hair loss disorders: a mini review
MicroRNAs may help diagnose and treat hair loss disorders.
research Implication of microRNA regulation in para-phenylenediamine-induced cell death and senescence in normal human hair dermal papilla cells
Hair dye ingredient PPD causes cell death and aging in human hair cells by altering microRNA levels.
Community Join
5 / 1000+ resultscommunity HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community Hope Medicine HMI-115 got 28M$ investment
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
community Since there is so much hype for cosmeRNA and HMI-115...
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.